CT-INTERACTIVE-BROKERS
28.2.2022 16:02:07 CET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Traders’ Insight Radio , a new podcast series featuring interviews with executives, thought leaders and market experts from across the financial services industry discussing topical themes impacting global markets and trading. Listeners familiar with Traders’ Insight , Interactive Brokers’ online resource for market commentary, will recognize in-house IBKR podcast hosts providing important context around the singular viewpoints being examined during the conversations.
Intended for a broad audience including both advanced traders and novice investors, Traders’ Insight Radio explores a wide range of interesting topics for any investor and enhances the suite of offerings already available through IBKR Campus , the company’s best-in-class educational resource. Recent and upcoming podcasts will feature conversations on the impact of artificial intelligence (AI) on markets, opportunities in foreign securities and views on cryptocurrency as the new digital asset class. For retail investors just starting out or advanced traders seeking to expand their knowledge base, IBKR Campus includes courses and content on trading, markets and current events, as well as overviews dedicated to IBKR’s products and trading platforms – and now, notable podcast interviews.
“We continue to focus on providing investors with the educational tools needed to improve their understanding of financial markets and trading,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Traders’ Insight Radio complements the resources already available through IBKR Campus and is a new and entertaining way all investors can easily access and benefit from expertise across the finance industry.”
The series was introduced in January and early episodes include a two-part interview with Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, discussing his early trading days as an options market maker and how he successfully introduced technology to the trading floor. Listeners will benefit from Mr. Peterffy’s perspective on a variety of subjects such as cryptocurrency, monetary policy and the impact of rising rates and inflation on the economy, while hearing anecdotes from his storied career. To listen to Mr. Peterffy’s podcast interviews, please visit:
Part 1: "You Mean You Don't Have to Know Anything to Do This?"
Part 2: "Mr. Sosnick, I Do Find You Increasingly Useless"
The latest episodes of Traders’ Insight Radio are available for free on the Traders’ Insight blog, through Interactive Brokers’ trading platforms including Trader Workstation, Client Portal and IBKR Mobile and popular podcasting services including Apple Podcast, Google Podcast, Podbean and Spotify.
For the full suite of free IBKR Campus resources, please see below and visit ibkr.com/campus .
Traders' Academy : Investors can improve their understanding of the products, tools and markets available through Interactive Brokers’ Trader Workstation, Client Portal, IBKR Mobile and TWS API applications.
IBKR Webinars : Investors can watch, listen and learn about current market topics and IBKR tools through live and recorded webinars.
Traders' Insight : Investors can watch, read or listen to market commentary from more than 70 industry professionals, including the new Traders’ Insight Radio.
IBKR Quant : A blog intended for quantitative professionals with an interest in programming, deep learning, IBKR API, AI, Blockchain and other transformative technologies influencing modern markets.
Student Trading Lab : A free online resource for educators looking to blend finance or computer science classwork with real-world trading experience.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom